• 한방비만학회지
• /
• 제9권2호
• /
• pp.33-45
• /
• 2009

Objectives This study was performed to evaluate the relation between hair tissue mineral elements(HTME) and Heart rate variability(HRV) of the metabolic syndrome(MS). Methods 89 persons(41-69 ages) who visited Oriental hospital for medical examination were divided MS group(n=22) and control group(n=67). HTME and HRV were compared, and were analyzed correlation with five contents of the MS. Results (1) In total subjects, waist circumference had a positive correlation with Pb. Blood pressure had a negative correlation with Mg. High density lipoprotein cholesterol(HDL-chol) had a negative correlation with Pb, Sb and K, while positive correlation with Ca/K. Triglyceride(TG) had a negative correlation with Mg and Na/K, while positive correlation with K and Ca/Mg. (2) In total subjects, TG and fasting blood sugar(FBS) had negative correlation with high frequency(HF), while positive correlation with low frequency/high frequency ratio(LF/HF). (3) In MS group, most of the level of toxic minerals were higher, and the level of major nutritional minerals were lower, but there were no statistical signficance. In two groups, there is no contrast between the correlations of the MS contents and HTME. (4) In MS group, HF was significantly lower and LF/HF was higher than normal group. LF/HF had a negative correlation with waist circumference in MS group, while positive correlation in normal group. (5) In total subjects, TP had a positive correlation with Mg. In two groups, there is no contrast between the correlations of the MS contents and HRV. However LF/HF had a positive correlation with Na in MS group, TP and LF had negative correlation with Ca, while RMSSD and HF had negative correlation with Cu in normal group. Conclusion These results may suggest that HTME and HRV are useful in diagnosing and preventing the metabolic syndrome.

• 한방재활의학과학회지
• /
• 제24권4호
• /
• pp.155-162
• /
• 2014

Objectives Advanced researches on the relationship between obesity and heart rate variability (HRV), heretofore, focused on characteristics of HRV depending on the state of obesity. However, the previous researches have not quantified predictive power of HRV toward the obesity-related variables, which is rather more meaningful for clinicians who regularly treat obese patients. Hence, we designed a research to investigate whether HRV could predict serum levels of obesity-related metabolites. Methods Ninety obese premenopausal women meeting the inclusion criteria were recruited. The HRV test, blood sampling, and measurement of physical traits were conducted. Multiple regression analysis of the measurement data was carried out, putting obesity-related metabolites (insulin, glucose, triglyceride, hs-CRP, HDL, LDL, total cholesterol) as outcome variables and the others as predictors. To select appropriate predictive variables, the Akaike's Information Criterion (AIC) was applied. Normality and homoskedasticity of residuals for each model were tested to identify if there were any violations of the regression analysis's basic assumption. Logarithm transformation was used for the values of the concentration of metabolites and the HRV. Results The regression model including Total Power (TP) value and BMI had significant predictive power for serum insulin concentration (F(2, 88)=835.7, p<0.001, $R^2=0.95$). The regression coefficient of ln (TP) was -0.1002. However, it was not sure if the HRV could predict concentrations of other metabolites. Conclusions The results suggest that the Total Power (TP) value of the HRV can predict the level of serum insulin. If the BMI could be assumed as being constant, when the TP value is multiplied by n, the predicted change of insulin could be drawn by multiplying $n^{-0.1002}$. The uncertainty of this model can be assumed as approximately 5%.

• 동의생리병리학회지
• /
• 제23권3호
• /
• pp.685-694
• /
• 2009

This experimental study was designed to investigate the inhibitory effects of ethanol extract of modified Yukgunja-tang(mYGJT) on high-fat diet-induced obesity and hyperlipidemia in Sprague-Dawley rats, Animals were divided into normal, control, mYGJT(100 mg/kg and 200 mg/kg) treated groups. Obesity with hyperlipidemia was induced by high fat diet treatment for 6 weeks. mYGJT was given to the amimals by oral gavage for 4 weeks, starting at the high-fat diet regimen, The effect of mYGJT on the differentiation of 3T3 L1 adipocytes in vitro and serological paramamters for obesity and hyperlipidemia in vivo were evaluated, mYGJT significnatly inhibited the differentiation of 3T3 L1 adipocytes in a concentration dependent manner. mYGJT treatment siginficantly reduced body weight, abdominal and epididymal fat weight, and FER(Food Efficiency Ratio) compared with control group in a dose dependent manner. It also signficantly inhibited the levels of serum total lipid, triglyceride, phospholipid, total cholesterol, LDL, AI(Atherosclerosis Index) and returned the serum HDL to normal. Total lipids, triglycerides and cholesterols in the liver, as well as malondialdehyde(MDA) and hydroxy radical in the serum were significantly reduced. However, superoxide dismutase(SOD) activity was significantly increased in mYGJT treated group compared with control group. Finally, mYGJT treatment signficantly decreased the MDA and protein carbonyl concentrations of the hepatic homogenate but signficantly increased the activities of SOD, GSH-Px and Catalase. Taken together, these results suggest that mYGJT can be clinically useful in inhibiting high-fat diet-induced obesity and hyperlipidemia.

• 대한임상검사과학회지
• /
• 제39권1호
• /
• pp.31-36
• /
• 2007

The purpose of the clinically reportable range (CRR) in clinical chemistry is to estimate linearity in working range. The reportable range includes all results that may be reliably reported, and embraces two types of ranges: the analytical measurement range (AMR) is the range of analyte values that a method can directly measure on the specimen without any dilution, concentration, or other pretreatment not part of the usual assay process. CAP and JCAHO require linearity on analyzers every six months. The clinically reportable range is the range of analyte values that a method can measure, allowing for specimen dilution, concentration, or other pretreatment used to extend the direct analytical measurement range. The AMR cannot exceed the manufacturer's limits. Establishing AMR is easily accomplished with Calibration Verification Assessment and experimental Linearity. For example: The manufacturer states that the limits of the AST on their instrument are 0-1100. The lowest level that could be verified is 2. The upper level is 1241. The verified AMR of the instrument is 2-1241. The lower limit of the range is 2, because that is the lowest level that could be verified by the laboratory. The laboratory could not use the manufacturer's lower limit of 2 because they have not proven that the instrument values below 2 are valid. The upper limit of the range is 1241, because although the lab has shown that the instrument is linear to 1241, the manufacturer does not make that claim. The laboratory needs to demonstrate the accuracy and precision of the analyzer, as well the validation of the patient AMR. Linearity requirements have been eliminated from the CLIA regulations and from the CAP inspection criteria, however, many inspectors continue to feel that linearity studies are a part of good lab practice and should be encouraged. If a lab chooses to continue linearity studies, these studies must fully comply with the calibration/calibration verification requirements of CLIA and/or CAP. The results of lower limit and upper limit of clinically reportable range were total protein (2.1 - 79.9), albumin (1.3 - 39), total bilirubin (0.2 - 106.2), alkaline phosphatase (13 - 6928.2), aspartate aminotransferase (24 - 7446), alanine aminotransferase (13 - 6724.2), gamma glutamyl transpeptidase (16.64 - 9904.2), creatine kinase (15.26 - 4723.8), lactate dehydrogenase (127.66 - 13231.8), creatinine (0.4 - 129.6), blood urea nitrogen (8.67 - 925.8), uric acid (1.6 - 151.2), total cholesterol (48.52 - 3162), triglycerides (36.91 - 3367.8), glucose (31 - 4218), amylase (21 - 6694.2), calcium (3.1 - 118.2), inorganic phosphorus (1.11 - 108), HDL (11.74 - 666), NA (58.3 - 1800), K (1.0 - 69.6), CL (38 - 1230).

• 동의생리병리학회지
• /
• 제21권3호
• /
• pp.605-610
• /
• 2007

This experimental study was performed to evaluate the effects of ehtanol extract of Purple Solanum tuberosum L(EPSTL) on obesity and hyperlipidemia in rats induced by high fat diet. Sprague-Dawley rats were divided into normal group, control group, EPSTL (100 mg/kg and 200 mg/kg) treated group. EPSTL was orally administered to the obese rats by high fat diet for 6 weeks. The effect of EPSTL on obesity and hyperlipidemia were examined in vitro and in vivo as follows : EPSTL effectively inhibited the differentiation of 3T3-L1 adipocytes in a concentration dependent manner. EPSTL significantly lowered body weight of rats fe high fat diet for 6 weeks from 4 weeks treatment compared with untreated control. EPSTL significantly reduced the weight of retroperitoneal fat only at 100 mg/kg and epididymal fat pad in rats fed high fat diet for 4 weeks at 100 and 200 mg/kg. EPSTL significantly reduced the level of triglyceride at 200 mg/kg, while EPSTL tended to lower the levels of total lipid and phospholipid in rats fed high fat diet for 4 weeks with no significance. EPSTL significantly attenuated the level of total cholesterol, LDL and atherosclerosis index (Al) as well as increased the level of HDL at 200 mg/kg. EPSTL significantly reduced the levels of total lipid and triglyceride of hepatic tissues in rats fed high fat diet for 4 weeks at 200 mg/kg. EPSTL significantly lowered the level of insulin, while it did not affect leptin compared with untreated control. Taken together, these results suggest that EPSTL can be used for the treatment or prevention of hyperlipidemia and obesity.

• 동의생리병리학회지
• /
• 제22권6호
• /
• pp.1626-1632
• /
• 2008

Among patients who are receiving treatments at an oriental medical hospital for various symptoms and diseases, patients whose main disease is accompanied by metabolic syndrome with abnormal liver function. This research was performed in order to observe the progression of changes in the liver function and serum lipid profile after the oriental medical treatments to patients who have been receiving oriental medical treatment for various other diseases and have been diagnosed as having metabolic syndrome at their first visit to the hospital based on NCEP ATP III diagnosis criteria and WHO Asia Pacific region criteria. Total number of subject patients were 39cases(mean age:55.58${\pm}$2.09 years) which had 20 male and 19 female. For the references for hepatic enzyme levels and blood lipid profile were measured in before treatment and four times after treatments(every 2.31${\pm}$06.17 weeks). Serum AST was 48.86${\pm}$7.46 IU/L before oriental medical treatment. After the treatment, 40.63${\pm}$4.69, 43.12${\pm}$5.46, 37.82${\pm}$4.52 IU/L were measured where although the level decreased to the normal level compared to pre-treatment, the value was not significant statistically(P>0.05). ALT was 66.26${\pm}$11.01 IU/L before oriental medical treatment. After the treatment 62.10${\pm}$8.20, 61.10${\pm}$8.76, 43.79${\pm}$5.68 were measured where although the level decreased, abnormally high level was maintained. The last result was significant statistically(P<0.05) compared to pre-treatment. ALP was 193.06${\pm}$14.20 IU/L before oriental medical treatment. After the treatment, 176.80${\pm}$6.48, 177.46${\pm}$11.81, 162.41${\pm}$9.06 where although compared to pre-treatment the last result was significant statistically(P<0.05), the change was within the normal range. ${\gamma}$-GGT was 87.83${\pm}$12.59 IU/L before oriental medical treatment. After the treatment, progressively near normal level was achieved with 118.73${\pm}$46.45, 85.03${\pm}$17.12, 70.64${\pm}$10.93 and the last result was statistically significant compared to pre-treatment (P<0.05). Blood triglyceride was 217.63${\pm}$32.18 mg/dL before oriental medical treatment. After treatment 215.09${\pm}$22.18, 189.93${\pm}$22.44, 191.22${\pm}$18.51 where abnormal values continued even after treatment although results was not statistically significant compared to pre-treatment(P>0.05). Total-cholesterol was 197.28${\pm}$9.24 mg/dL before oriental medical treatment, after treatment 201.55${\pm}$11.13, 186.87${\pm}$8.77 and 186.68${\pm}$7.61 were measured that results were not statistically significant compared to pre-treatment(P>0.05). HDL-cholesterol was 41.88${\pm}$2.38 mg/dL before oriental medical treatment, after treatment 48.75${\pm}$4.22, 44.10${\pm}$1.91, 48.00${\pm}$2.06 the results were not statistically significant compared to pre-treatment(P>0.05). LDL-cholesterol was 111.66${\pm}$13.08 mg/dL before oriental medical treatment, after treatment 109.94${\pm}$10.18, 101.79${\pm}$8.63, 104.00${\pm}$6.98 the results were not statistically significant compared to pre-treatment(P>0.05). With such results, even if common oriental medical treatments were given to metabolic syndrome patients with abnormal liver function, the liver function was confirmed not to be aggravated, and the concentration of lipids in the blood was confirmed not to be affected in most patients.

• 한국식품영양과학회지
• /
• 제33권8호
• /
• pp.1302-1310
• /
• 2004

본 웹기반 영양상담 프로그램은 전보(17)에서 개발된 고지혈증환자를 위한 영양상담 프로그램에 환자들의 추후관리를 위해 재진상담 프로그램을 개발하여 삽입하였다. 개발된 재진상담 프로그램은 식습관 조사, 식품섭취빈도 조사 및 온라인 상담 파일로 구성되었으며 온라인 상담 파일에 채팅룸을 두어 환자들과 실시간으로 상담할 수 있도록 하였다. 8주간의 웹을 이용한 영양상담 후 신체계측치의 변화에서 체질량지수는 고콜레스테롤혈증군과 고중성지방혈증군 모두에서 감소하였고, 허리/엉덩이 둘레비는 고콜레스테롤혈증군 중 남자에게서 유의하게 감소하였다(p<0.05). 혈청 지질의 변화는 고콜레스테롤혈증군은 총콜레스테롤과 LDL-콜레스테롤이 영양상담 후에 유의하게 감소하였고(p<0.01), 고중성지방혈증군은 중성지방이 유의하게 감소하였으며(p<0.01), HDL-콜레스테롤은 유의하게 증가하였다(p<0.05). 영양소 섭취의 변화는 두군 모두에서 영양상담 후에 에너지 섭취량이 감소하였고 특히 열량영양소 중 지방의 섭취량이 51.9∼52.5 g에서 영양상담 후 32.5∼33.3 g으로 유의하게 감소하였다(p<0.01). 그러나 1,000 kcal당 영양소 섭취량을 비교하여 보면 영양상담 후 환자들은 열량은 낮으면서 영양소 밀도가 높은 식품을 선택하여 비타민 B$_1$과 B$_2$는 유사하게 섭취하였으며 비타민 C, 칼슘 및 철분은 오히려 높게 섭취하였다. 지방산 섭취의 변화는 영양상담 후 두군 모두에서 포화지방산의 섭취량이 유의하게 감소하였으며, 이로 인해 포화지방산, 단일불포화지방산, 다가불포화지방산의 섭취비율이 고지혈증 치료지침의 권장비율에 속하였다. 콜레스테롤 섭취량 역시 영양상담 후에 유의하게 감소하였다(p<0.01). 이러한 연구의 결과로 웹상에서의 재진상담을 통하여 지속적이고 반복적인 추후관리가 효율적으로 이루어짐 에 따라 고지혈증 환자에게 바람직한 식사섭취형태가 정착되고, 혈청 지질에도 긍정적인 효과를 줌으로서 정보화 시대에 맞는 새로운 영양상담 매체로서의 인터넷의 가능성을 제시하였다.

• 대한한의학방제학회지
• /
• 제22권1호
• /
• pp.167-176
• /
• 2014

Objectives : This study investigated the improvement effects of Gangjihwan (DF) and combination of Gangjihwan and Gamisochehwan (GSH) on nonalcoholic fatty liver disease in a high fat diet-induced obese mouse model. Methods : Eight-week-old C57BL/6N mice were divided into five groups: a normal lean group given a standard diet, an obese control group given a high fat diet, and atorvastatin, DF, and DF+GSH groups given a high fat diet with atorvastatin (10 mg/kg), DF (40 mg/kg), and DF+GSH (80 mg/kg), respectively. After 8 weeks of treatment, body weight gain, blood lipid markers, ALT concentrations, liver weight and histology were examined. Results : 1. Body weight gain was significantly decreased in DF, DF+GSH and atorvastatin groups compared with control. The extent of decreases was eminent in DF+GSH group. 2. Circulating concentrations of total cholesterol, HDL-cholesterol and LDL-cholesterol were decreased in DF, DF+GSH and atorvastatin groups compared with control. The decreases were significant in DF+GSH and atorvastatin groups. 3. Liver weights were decreased in DF, DF+GSH and atorvastatin groups compared with control. In particular, liver weight was significantly reduced only in DF+GSH group. 4. Hepatic lipid accumulation was significantly decreased in DF, DF+GSH and atorvastatin groups compared with control, and the magnitude of which was more effective in DF+GSH group than in DF-only group. 5. Circulating ALT concentrations were decreased in DF, DF+GSH and atorvastatin compared with control, but ALS levels were significantly reduced only in DF+GSH group. Conclusions : In conclusion, these results suggest that DF decreases body weight gain, improves blood lipid metabolism, and reduces liver weight and hepatic lipid accumulation, contributing to the improvement of nonalcoholic fatty liver disease. In addition, these effects were more effective in DF+GSH combination group than in DF-only group.

• 한국식품영양과학회지
• /
• 제46권3호
• /
• pp.279-288
• /
• 2017

본 연구에서는 발효콩 유지가 비만 억제 및 예방, 3T3-L1 지방전구세포의 성장 및 분화 억제 효과를 관찰하기 위해 실험을 실시하였다. 3T3-L1 지방전구세포에 발효콩 유지를 처리하여 세포생존율을 측정한 결과, NF군 $100{\mu}g/mL$에서 3T3-L1 지방전구세포의 생존율을 유의적으로 감소시켜 세포독성이 나타났다. 분화를 유도한 다음 세포 내 triglyceride 함량을 측정한 결과, 비발효콩 유지(NF) 처리군보다 발효콩 유지처리군에서 triglyceride 함량 저해 효과가 높게 나타났으며, 특히 BS, LBA, BLO군 순으로 높게 나타났다. 또한, BS군, LBA군, BLO군 순으로 지방세포분화 관련 유전자인 $PPAR{\gamma}$의 mRNA 발현을 농도 의존적으로 감소시켰으며, $PPAR{\gamma}$ 유전자와 상관관계에 있는 $C/EBP{\alpha}$ 유전자도 농도 의존적으로 감소시켰다. 그리고 adiponectin 유전자의 발현은 농도 의존적으로 증가시켰다. 고지방식이로 비만을 유도한 C57BL/6J 생쥐를 이용하여 항비만 활성을 관찰한 결과, 총 체중증가량은 대조군에 비해 4주째에 감소하는 경향이 나타났다. 혈액 내 지질농도를 측정한 결과 중성지방, 총콜레스테롤, LDL-콜레스테롤 함량은 LBA, BLO군에서 유의적으로 낮게 나타났으며(P<0.05), HDL-콜레스테롤 함량은 대조군보다 증가하였으나 유의적인 차이는 나타나지 않았다. 동맥경화 지수인 AI(atherogenic index)는 대조군보다 감소시키는 경향을 보였다. 비만관련 호르몬인 adiponectin의 농도는 SO, BS, LBA, BLO군에서 유의적으로 증가하였고(P<0.05), insulin 농도는 유의적으로 감소하였다(P<0.05). Leptin은 대조군보다 감소하였으나 유의적인 차이는 나타나지 않았다. 따라서 이러한 결과를 종합하여 볼 때 발효콩 유지가 3T3-L1 지방전구세포의 mRNA 단계에서부터 지방분화를 억제하여 항비만 활성을 가지고 있는 것으로 추정되고, 고지방식이로 비만이 유도된 C57BL/6J 생쥐에서 총체중을 감소시키고, 혈액 내 지질농도인 triglyceride와 총콜레스테롤, LDL-콜레스테롤 및 HDL-콜레스테롤과 비만관련 호르몬인 adiponectin, insulin, leptin을 조절하여 항비만 활성을 가지고 있는 것으로 확인되었다. 이 결과로 발효콩 유지가 항비만 생리활성을 나타내는 새로운 식품 소재로서 이를 활용한 기능성 식품 개발의 가능성이 있다고 생각된다.

• 한국가금학회지
• /
• 제45권3호
• /
• pp.201-207
• /
• 2018

본 연구는 산란 후기사료에 마늘발효액을 수준별로 첨가 급여시 산란계의 생산성, 계란품질 및 혈액성상에 미치는 영향을 구명하고자 실시하였다. 79주령 로만브라운 산란계를 4개 처리구 6반복으로 반복 당 18수씩 총 432수를 배치하였고, 각 처리구에 마늘발효액을 0%, 0.05%, 0.10% 및 0.20%로 4주간 급여하였다. 산란 수와 난중은 매일 조사하였고, 계란품질, 난황지방산 및 혈액성상은 사양실험 종료 후 분석하였다. 본 연구결과, 산란율과 사료요구율은 마늘발효액 급여구에서 대조구에 비하여 수치적으로 개선되었지만, 처리구간에 통계적 차이가 없었고, 난각강도와 두께도 마늘발효액 첨가수준에 따른 유의성이 없었다. 계란의 난백 높이와 호우유닛은 마늘발효액 첨가수준에 따라 일관적으로 증가하여 0.20%급여구에서 제일 높게 나타났으며, 대조구에 비하여 통계적으로 차이를 보였다(P<0.05). 난황지방산은 마늘발효액의 0.10%와 0.20% 첨가구에서 포화지방산은 감소되었고, 단일불포화지방산과 전체 불포화지방산은 현저하게 증가하였다(P<0.05). 혈중 알부민, AST 및 ALT은 처리구간에 차이가 없었지만, 중성지방과 콜레스테롤은 0.20% 급여구에서 대조구에 비해 매우 감소하였다(P<0.05). 또한 HDL콜레스테롤은 마늘발효액 0.10%와 0.20% 급여구에서 대조구에 비하여 유의적으로 증가하였고(P<0.05), 세포성 면역능 지표인 IL-2 mRNA와 CD4+CD8+의 비율도 0.10%와 0.20% 급여구에서 다른 처리구에 비하여 통계적으로 높게 나타났다(P<0.01). 본 실험 결과, 산란 말기 사료에 마늘발효액 0.20% 수준의 급여로 대조구에 비하여 계란품질과 건강 및 혈중 면역인자는 개선되었다.